News

21 Jun 2018

Human Tissue Experts REPROCELL Launch New Customized Primary Cell Isolation Services

REPROCELL’s BioServe and Biopta tissue procurement networks combine to create a new service isolating human primary cells.
Read More >>

13 Jun 2018

REPROCELL's footprint extends to serve life sciences in India

REPROCELL India (formerly BioServe Biotechnologies) is a state-of-the-art biotechnology company with a mission to serve the life sciences research ecosystem.
Read More >>

25 May 2018

Do animal experiments translate to humans? A report by Elsevier and Bayer uses big data to shed new light on a hotly debated topic

At REPROCELL, we are continually striving to expand our range of human fresh tissue and 3D models of drug safety and efficacy. REPROCELL hosts the only catalogue of human fresh tissue assays with searchable categories of tissue type, receptor and endpoints across a range of therapeutic areas.
Read More >>

18 May 2018

Factors to consider when planning a iPSC reprogramming project

When you are considering beginning a project involving iPSC reprogramming, there are several factors to consider when choosing a reprogramming technology and a service provider.
Read More >>

1 2 3 4 >>

Visit REPROCELL Booth 107 at the SPS Annual Meeting, Berlin, 24-27 September 2017

15/09/2017

This year’s Safety Pharmacology Society (SPS) Annual Meeting will be held in the Maritim Hotel, Berlin, Germany, on 24-27 September 2017. See http://www.safetypharmacology.org/am2017/program.asp.

 

REPROCELL will be at booth 107.

 

Present from REPROCELL Europe Ltd will be:

  • Chirag Tawde – Sales Director EMEA
  • Dr Graeme Macluskie – “Meet the Expert” REPROCELL Europe Ltd head of R&D.

 

Dr Graeme Macluskie is an expert in the development, implementation and validation of new tissue assays to address clinical safety, efficacy, ADME and toxicology during the early drug discovery process.

 

Take part in our Competition

Guess the number of rice grains in our culture media bottle and you could win a set of 2 specially engraved REPROCELL whisky glasses, 1 bottle Scottish whisky and 1 bottle of Japanese whisky.

 

About REPROCELL

REPROCELL is a global biotech company specializing in stem cell technologies, providing one of the world’s largest biorepositories of human cell, DNA and RNA samples, 2D and 3D cell culture products, induced pluripotent stem cells (iPSCs), and expert contract research services using live human tissue. Our integrated workflow covers every step of the drug discovery process used in biotech and pharma companies and institutions around the world. As a global technology partner, REPROCELL has the history, expertise and flexibility to accelerate your research.

 

  • The latest RNA reprogramming technology
  • Fresh human tissue assays tailored to your needs
  • Prospective bio specimen collection for e.g. gene and protein analysis, iPSC generation
  • Cutting edge and personalized 3D cell-based assays

 

About the SPS Annual Meeting

Highlights of the Annual Meeting 2017:

 

  • A dynamic forum for best practice sharing within industry, CRO’s, academics and regulators
  • Scientific Sessions organized by SPS Members
  • Sessions on some of the hottest topics in safety pharmacology related research
  • 6 CE Courses taught by experts in the field
  • Plenary Keynote Speakers by a key opinion leaders
  • Exhibit hall offering access to industry vendors
  • Poster sessions featuring cutting-edge research
  • Networking opportunities with a global community of scientists from regulatory, industry, and academia
  • Award opportunities to bring together Student and Jr. Investigators with seasoned scientists, while sharing their research
  • Exhibitor Sponsored Sessions by leading technology and service providers showcasing their new offerings and research

 

http://www.safetypharmacology.org/am2017/.

 

About the SPS

The Safety Pharmacology Society is a nonprofit organization that promotes knowledge, development, application, and training in Safety Pharmacology—a distinct scientific discipline that integrates the best practices of pharmacology, physiology and toxicology. The objective of Safety Pharmacology studies is to further the discovery, development and safe use of biologically active chemical entities by the identification, monitoring and characterization of potentially undesirable pharmacodynamic activities in nonclinical studies. The Safety Pharmacology Society also supports the human safety of drugs and biologicals by fostering scientific research, education, and dissemination of scientific information through meetings and other scientific interactions.

 

The Society is committed to uniting the global safety pharmacology community in the development and safe medical use of biologically active molecular entities by bridging across disciplines to allow the identification, characterization, and monitoring of potentially undesirable pharmacodynamic activities in nonclinical studies and guiding their translation into clinical trials.

 

http://www.safetypharmacology.org/am2017/.

Live chat by BoldChat